Home » Pfizer and BioNTech Start COVID-19 Vaccine Trial in U.S.
Pfizer and BioNTech Start COVID-19 Vaccine Trial in U.S.
Pfizer and BioNTech have started a U.S. trial of COVID-19 vaccine candidates at the NYU Grossman School of Medicine and the University of Maryland School of Medicine.
The phase 1/2 study will assess the safety, immunogenicity and optimal dose of four mRNA vaccine candidates in a single, continuous trial. The first stage will enroll up to 360 healthy subjects between the ages of 18-55 and 65-85 years of age.
The drugmakers are also conducting the trial in Germany — the first COVID-19 vaccine trial in that country.
Upcoming Events
-
07May
-
14May
-
30May